Avenue Therapeutics Inc. buy stratec
Start price
13.07.18
/
50%
€52.77
Target price
04.11.19
€102.83
Performance (%)
0.00%
End price
04.11.19
-
Summary
This prediction ended on 04.11.19 with a price of -. The BUY prediction by stratec closed unchanged from the start price. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Avenue Therapeutics Inc. | - | - | - | - |
| iShares Core DAX® | -3.520% | -4.987% | 1.926% | 50.820% |
| iShares Nasdaq 100 | 0.261% | 1.102% | 15.434% | 90.843% |
| iShares Nikkei 225® | -4.953% | -3.352% | 29.010% | 51.211% |
| iShares S&P 500 | -0.823% | -0.042% | 10.814% | 62.945% |
Comments by stratec for this prediction
In the thread Avenue Therapeutics diskutieren
Avenue Therapeutics with positive results from its first Phase 3...
... clinical trial assessing IV tramadol for the treatment of patients with moderate-to-moderately severe pain following bunionectomy surgery. The study met the primary endpoint of a statistically valid improvement in pain score over 48 hours compared to placebo. Key secondary endpoints were also met. The results will be submitted for presentation at a future scientific conference or for publication.
A second Phase 3 evaluating IV tramadol patients following abdominoplasty surgery will commence next quarter.
Es gibt keinen Handelsplatz